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ABSTRACT 
When a patient suffers from end stage renal disease, the vascular access becomes the lifeline to perform 
regular haemodialysis (HD) treatment. The recommended first choice is the surgically created native 
Arterio-Venous Fistula (AVF). The AVF patency is limited due to stenosis, aneurysm and infections. The 
effect of access complications is uraemia progress, which jeopardizes patient survival. The overall aim of 
this thesis was to evaluate risk factors that cause AVF complications and to analyse interventions that might 
prevent AVF dysfunction. 
Study I: This was a prospective study that included 30 patients with a native AVF in the forearm acting as 
his/her own control. Far Infrared illumination (FIR) is a non-recognized method used by few centres in an 
attempt to improve AVF flow. The primary aim was to evaluate the effect of one single treatment with FIR 
of the AVF. FIR increased the blood velocity of the AVF from 2.1 to 2.3 m/s (p=0.02). The diameter of the 
arterialized vein increased from 0.72 to 0.80 cm (p=0.006). The change in AVF blood velocity correlated 
with baseline serum urate (p=0.004), and the change in venous diameter correlated with the baseline plasma 
orosomucoid level (p=0.005). 
Study II: The primary aim was to evaluate conditions that might lead to a dysfunctional AVF in a 
retrospective study comparing data from 66 patients in regular HD treatment (33 Cases with AVF 
dysfunction, 33 Controls without AVF dysfunction) during a two year follow-up. Cases had higher weekly 
doses of Erythropoiesis-Stimulating Agent (ESA), than Controls both before (mean 8312 U/w vs 4348, 
p=0.005) and after radiological AVF intervention/follow up (7656 vs 4477, p=0.018). 
Study III: This was a retrospective study of patients (N=174) with clinically suspected dysfunction of the 
AVF.  The primary aim was to evaluate to what extent the end-stage renal disease (ESRD) was related to a 
specific diagnosis and how radiological intervention affected the dysfunction of the AVF. AVF venous 
stenoses were the most frequent reason and were located mostly close to the anastomosis and to a lesser 
extent at the distal and proximal puncture sites. Arterial stenosis was significantly more frequent among 
patients with diabetic nephropathy (p < 0.001) and interstitial nephritis (p < 0.001). 
Study IV: The primary aim was to uncover risk factors in HD patients that could explain the occurrence of 
AVF dysfunction. This was a retrospective analysis of 473 patients in HD from two hospitals. The main 
finding was a higher weekly dose of ESA among Cases with AVF dysfunction versus Controls without 
dysfunction (8000 IU vs 5000, p<0.001). In patients with diabetes mellitus, HbA1c was higher among Cases 
than Controls (50 vs 38 mmol/mol, p<0.001).  
Conclusion: The AV Fistula patency among HD patients is limited due to various medical and surgical 
reasons. Besides radiological interventions, the need for other non-invasive treatment options such as FIR 
light may improve the maturation and patency of the AVF. To improve further AVF patency, strategies 
concerning patient selection, anaemia treatment and glycaemic control are future options for preventing 
AVF complications.  
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